Recent Company News

• 07:33 PM ET Mar 16, 2026
  

  Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders?

• 03:20 PM ET Mar 16, 2026
  

  $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

• 08:04 AM ET Mar 13, 2026
  

  Barinthus Biotherapeutics reports FY EPS ($1.64) vs FactSet ($1.50) [2 est, ($1.77)-(1.23)]

• 06:22 AM ET Feb 23, 2026
  

  Barinthus Biotherapeutics amends merger agreement with Clywedog - 8-K ($0.63, 0.00)

• 08:03 AM ET Dec 10, 2025
  

  Barinthus Biotherapeutics announces update on Phase 1 Avalon clinical trial of VTP-1000 for the treatment of Celiac disease ($0.68, 0.00)

• 07:35 AM ET Nov 07, 2025
  

  Barinthus Biotherapeutics reports Q3 EPS ($0.36) vs FactSet ($0.40) [2 est, ($0.45)-(0.34)] ($1.19, 0.00)

• 11:14 AM ET Oct 06, 2025
  

  StreetAccount M&A Summary: Week of 29-Sep

• 08:07 AM ET Sep 30, 2025
  

  Barinthus Biotherapeutics to combine with Clywedog Therapeutics in all-stock transaction ($1.48, 0.00)

• 08:11 AM ET Aug 07, 2025
  

  Barinthus Biotherapeutics reports Q2 EPS ($0.52) vs FactSet ($0.33) [2 est, ($0.37)-(0.29)] ($1.31, 0.00)

• 08:21 AM ET May 07, 2025
  

  Barinthus Biotherapeutics terminates CFO Gemma Brown as part of restructuring plan; discloses new data on VTP-300 at EASL Congress - 8-K ($1.00, 0.00)